Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan
© Lee et al; licensee BioMed Central Ltd. 2007
Received: 06 August 2006
Accepted: 17 July 2007
Published: 17 July 2007
Ertapenem is a once-a-day carbapenem and has excellent activity against many gram-positive and gram-negative aerobic, facultative, and anaerobic bacteria. The susceptibility of isolates of community-acquired bacteremia to ertapenem has not been reported yet. The present study assesses the in vitro activity of ertapenem against aerobic and facultative bacterial pathogens isolated from patients with community-acquired bacteremia by determining and comparing the MICs of cefepime, cefoxitin, ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-tazobactam, ciprofloxacin, amikacin and gentamicin. The prevalence of extended broad spectrum β-lactamases (ESBL) producing strains of community-acquired bacteremia and their susceptibility to these antibiotics are investigated.
Aerobic and facultative bacteria isolated from blood obtained from hospitalized patients with community-acquired bacteremia within 48 hours of admission between August 1, 2004 and September 30, 2004 in Chang Gung Memorial Hospital at Keelung, Taiwan, were identified using standard procedures. Antimicrobial susceptibility was evaluated by Etest according to the standard guidelines provided by the manufacturer and document M100-S16 Performance Standards of the Clinical Laboratory of Standard Institute. Antimicrobial agents including cefepime, cefoxitin, ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-tazobactam, ciprofloxacin, amikacin and gentamicin were used against the bacterial isolates to test their MICs as determined by Etest. For Staphylococcus aureus isolates, MICs of oxacillin were also tested by Etest to differentiate oxacillin-sensitive and oxacillin-resistant S. aureus.
Ertapenem was highly active in vitro against many aerobic and facultative bacterial pathogens commonly recovered from patients with community-acquired bacteremia (128/159, 80.5 %). Ertapenem had more potent activity than ceftriaxone, piperacillin-tazobactam, or ciprofloxacin against oxacillin-susceptible S. aureus (17/17, 100%)and was more active than any of these agents against enterobacteriaceae (82/82, 100%).
Based on the microbiology pattern of community-acquired bacteremia, initial empiric treatment that requires coverage of a broad spectrum of both gram-negative and gram-positive aerobic bacteria, such as ertapenem, may be justified in moderately severe cases of community-acquired bacteremia in non-immunocompromised hosts.
Ertapenem is a once-a-day parenteral β-lactam antimicrobial agent [1–6]. Preclinical in vitro studies have shown that this structurally unique carbapenem has excellent activity against many gram-positive and gram-negative aerobic, facultative, and anaerobic bacteria that, in general, are associated with community-acquired infections [1–6]. However, it has minimal activity against Pseudomonas aeruginosa, Acinetobacter species, and enterococci [1–6], and these pathogens usually are associated with nosocomial infections. Recent antimicrobial susceptibility surveillance data indicate that the organisms causing intra-abdominal, skin and soft tissue, and urinary tract infections and community-acquired pneumonia are highly susceptible to ertapenem in vitro [7–17]. However, the susceptibility of isolates of community-acquired bacteremia to ertapenem has not yet been reported. The objective of the present study is to assess the in vitro activity of ertapenem against aerobic and facultative bacterial pathogens isolated from patients with community-acquired bacteremia by determining and comparing the MICs of cefepime, cefoxitin, ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-tazobactam, ciprofloxacin, amikacin and gentamicin. In addition, the prevalence of ESBL producing strains of community-acquired bacteremia and their susceptibility to these antibiotics are investigated.
Chang Gung Memorial Hospital at Keelung is an 850-bed(including 55 ICU beds) teaching hospital offering a broad range of services in serving the healthcare needs of about 500,000 residents in northern Taiwan. It has approximately 21,000 admissions per year and mean duration of hospitalization of 8.2 days. Aerobic and facultative bacteria isolated from blood obtained from hospitalized patients with community-acquired bacteremia within 48 hours of admission between August 1, 2004 and September 30, 2004 in Chang Gung Memorial Hospital at Keelung were identified using standard procedures. Community-acquired bacteremia was diagnosed when clinically significant bacterial pathogens were isolated from the blood of hospitalized patients with fever of 38.0≧°C within 48 hours of admission and without admission in past two weeks. Cases with only one blood culture bottle positive for normal skin flora such as coagulase-negative staphylococci, Staphylococcus epidermidis, Staphylococcus saprophyticus and corynebacterium spp. were excluded. All bacillus, micrococcus and propionibacterium isolates which were considered contaminants and anaerobic bacteria were excluded. Clinically significant aerobic bacterial isolates were collected and stored in tryptic soy broth and frozen at -70°C.
MIC(μg/ml) breakpoints of susceptibility for each type of bacteria
MIC Breakpoint of Susceptibility (μg/ml)
Type of bacteria /Antibiotic
For quality control, standard control strains were included with each test run. The following organisms with acceptable MICs (μg/ml) limits were included as control strains according to CLSI M7-A7 : S. aureus ATCC 29213 (0.12–0.5 for ciprofloxacin, 4–16 for ceftazidime, 1–4 for cefepime, 0.25/4-2/4 for piperacillin/tazobactam), E. coli ATCC 25922 (0.004–0.016 for ciprofloxacin, 0.06–0.5 for ceftazidime, 0.016–0.12 for cefepime, 1/4-4/4 for piperacillin/tazobactam), P. aeruginosa ATCC 27853 (0.25–1 for ciprofloxacin, 1–4 for ceftazidime, 1–8 for cefepime, 1/4-8/4 for piperacillin/tazobactam), Streptococcus pneumoniae ATCC 49619 (0.06–0.25 for cefepime), Enterococcus faecalis ATCC 29212 (0.25–2 for ciprofloxacin, 1/4-4/4 for piperacillin/tazobactam).
According to CLSI M7-A7, MIC(μg/ml) breakpoints of susceptibility for each type of bacteria were listed in Table 1.
S. aureus isolates with oxacillin MIC of ≦2 μg/ml were regarded as oxacillin-sensitive S. aureus (OSSA), whereas isolates with oxacillin MIC of ≧4 μg/ml were regarded as oxacillin-resistant S. aureus (ORSA) according to criteria of S. aureus susceptibility to oxacillin in CLSI document. M7-A7 published in January 2006. Enterobacteriaceae isolates with ceftazidime MIC ≧2 μg/ml but MIC diminished at least 3 fold after addition of clavulanic acid were regarded as ESBL strains.
Results and dscussion
There were 70 male and 89 female. Ages ranged from 1 year to 95 years with mean 60.9 years. There were 147 adults (age ≧17 years, range 22–95 years, mean 65.2 years) and 12 pediatric patients (age ≦16 years, range 1–16 years, mean 3.2 years). Of the 159 cases of community-acquired bacteremia, the most likely primary foci of origin according to clinical manifestations are urinary tract infection 59, pneumonia 39, biliary tract infection 17, cellulitis 9, infective endocarditis 3, osteomyelitis 2, peritonitis 1, gastroenteritis 1, and esophagitis 1. The primary foci of origin of the remaining 27 cases of community-acquired bacteremia are unknown. A total of 159 aerobic bacterial pathogens from 159 patients enrolled at Chang Gung Memorial Hospital were collected. Most (95/159, 59.7%) of the isolates were facultative gram-negative bacilli. The most common organism found was E. coli, which accounted for 26.4% (42/159) of the total. There were only seven isolates (7/159, 4.4%) with ESBLs (E. coli – ESBL, 4; K. pneumoniae – ESBL, 3).
Although most OSSA were susceptible to the majority of agents tested, ertapenem had the most potent activity, based on values for inhibition of 50 % (MIC50) and 90% (MIC90) of the isolates. All isolates of OSSA were susceptible to ertapenem (17/17, 100 %). Ertapenem was the most active agent against enterobacteriaceae and demonstrated high potency based on MIC50 and MIC90 values. All isolates of enterobacteriaceae, including most ESBL strains, were susceptible to ertapenem (82/82, 100%) while not as susceptible to ceftriaxone (86.6 %). Among these 159 isolates, there were 38 E. coli isolates of which 4 (10.5%) were ESBL strains, and 13 K. pneumoniae isolates, of which 3 (23%) were ESBL strains. The prevalence of enterobacteriaceae with ESBLs in community-acquired bacteremia was 7/159, 4.4% in this study. In our hospital, there were 877 significant isolates including fungus, aerobic and anaerobic bacteria causing nosocomial infections in 2006. Among these 877 nosocomial isolates in our hospital in 2006, there were 151 E. coli isolates, of which 21 (14%) were ESBL strains, and 69 K. pneumoniae isolates, of which 22 (31.8%) were ESBL strains. The overall rate of ESBL strain among nosocomial isolates were 43/877 (4.9%). Although the overall rate of ESBL isolates among community-acquired bacteremia (4.4%) was close to that among nosocomial infections (4.9%), the rate of ESBL isolates among E. coli and K. pneumoniae were still higher in nosocomial infections. As expected, ertapenem and ceftriaxone had minimal activity against P. aeruginosa and enterococci. Among the nine ORSA isolates with oxacillin MICs ≧4 μg/ml, two ORSA isolates were mecA gene positive with amoxicillin/clavulanic acid MICs 32 μg/ml. The other seven ORSA isolates were mecA gene negative with amoxicillin/clavulanic acid MICs range 8–12 μg/ml, mean 11.4 μg/ml, indicating that mechanism of oxacillin resistance in these seven ORSA isolates was not due to mecA gene and was most likely due to hyperproduction of β-lactamases [19–22]. Two of the nine ORSA isolates were susceptible to amikacin, including one isolate that was also susceptible in vitro to ciprofloxacin and gentamicin; these two isolates resistant to all β-lactam antibiotics might lack resistance gene to other classes of antibiotics [19–22]. Based on the microbiology of community-acquired bacteremia, empiric treatment requires coverage of a broad spectrum of both gram-negative and gram-positive aerobic bacteria. In this in vitro study, ertapenem was the most active of the agents evaluated against the predominant pathogens – enterobacteriaceae and S. aureus. As anticipated, ertapenem had minimal activity against P. aeruginosa and enterococci, which was recovered relatively infrequently from community-acquired bacteremic infections. Because of the low frequency of isolation of P. aeruginosa and doubtful pathogenicity of enterococci in immune competent hosts, initial empiric antimicrobial regimens for bacteremic infections need not include agents specifically directed against these organisms. However, if P. aeruginosa is clearly identified as a pathogen in these patients, specific antipseudomonal coverage would be indicated.
In summary, ertapenem was highly active in vitro against many aerobic and facultative bacterial pathogens commonly recovered from patients with community-acquired bacteremia. Ertapenem had more potent activity than cefepime, cefoxitin, ceftriaxone and piperacillin-tazobactam against methicillin-susceptible S. aureus and was more active than any of these agents against enterobacteriaceae including strains with ESBL.
Community-acquired bacterial blood stream infections are common in clinical practice. Septicemia secondary to other foci of infections are caused by gram-negative and gram-positive aerobic and facultative bacteria, although E. coli and S. aureus remain the predominant pathogens. Non-fermentative gram-negative bacteria, which tend to be associated with nosocomial infections, are infrequently involved in community-acquired infections. Based on the microbiology pattern of community-acquired bacteremia, initial empiric treatment that requires coverage of a broad spectrum of both gram-negative and gram-positive aerobic bacteria, such as ertapenem, may be justified in moderately severe cases of community-acquired bacteremia in non-immunocompromised hosts. However, effect of ertapenem on the gut flora is still a concern.
This study is financially supported by Chang Gung Memorial Hospital. We wish to thank Ms. Yi Mui Chan and Ms Hsiang Ju Shih for laboratory assistance and Ms. Chung Wei Lue for reviewing the English grammar of the manuscript.
- Fuchs PC, Barry AL, Brown SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother. 2001, 45: 1915-1918. 10.1128/AAC.45.6.1915-1918.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Livermore DM, Carter MW, Bagel S, Wiedemann B, Saquero F, Loza E, Endtz HP, Nguyen J, Nord CE, Struelens MJ, Nonhoff C, Turnidage J, Bell J, Zbinden R, Pfister S, Mixson L, Shungu DL: In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother. 2001, 45: 1860-1867. 10.1128/AAC.45.6.1860-1867.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Prous JR, Fairley L, Fleischer J: Ertapenam: the first group 1 carbapenem. Drugs Today. 2005, 41: 1-16.Google Scholar
- Shah PM, Isaacs RD: Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother. 2003, 52: 538-542. 10.1093/jac/dkg404.View ArticlePubMedGoogle Scholar
- Livermore DM, Sefton AM, Scott GM: Properties and potential of ertapenem. J Antimicrob Chemother. 2003, 52: 331-344. 10.1093/jac/dkg375.View ArticlePubMedGoogle Scholar
- Wexler HM: In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother. 2004, 53 (Suppl S2): ii23-ii28.Google Scholar
- Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waites KB: In vitro activity of ertapenem(MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agent. 2002, 20: 136-140. 10.1016/S0924-8579(02)00129-2.View ArticleGoogle Scholar
- Livermore DM, Oakton KJ, Carter MW, Warner M: Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent-lactamases. Antimicrob Agents Chemother. 2001, 45: 2831-2837. 10.1128/AAC.45.10.2831-2837.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Guillermo OR, Caballero-Lopez J, Friedland IR, Gail LW, Carides A: Study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis. 2002, 34: 1076-1083. 10.1086/339543.View ArticleGoogle Scholar
- Goldstein EC, Citron DM, Merriam CV, Warren Y, Tyrrell KL, Gesser RM: General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Activity of ertapenem in skin infections. Clin Infect Dis. 2002, 35 (Suppl 1): S119-S125. 10.1086/341932.View ArticlePubMedGoogle Scholar
- Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Guidelines for CAP in adults. Clin Infect Dis. 2003, 37: 1405-1433. 10.1086/380488.View ArticlePubMedGoogle Scholar
- Lipsky BA, Berendt AR, Deery HG, Embil JM, Warren SJ, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS: Diagnosis and Treatment of Diabetic Foot Infections. Guidelines for diabetic foot infections. Clin Infect Dis. 2004, 9: 885-910. 10.1086/424846.View ArticleGoogle Scholar
- Tellado J, Woods GL, Gesser R, McCarroll K, Teppler H: Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. Surg Infect. 2002, 3: 303-314. 10.1089/109629602762539535.View ArticleGoogle Scholar
- Alhambra1 A, Cuadros JA, Cacho J, Gómez-Garcés JL, Alós JI: In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother. 2004, 53: 1090-1094. 10.1093/jac/dkh218.View ArticlePubMedGoogle Scholar
- Mazuki JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M, Kudsk KA, Yowler C: The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections. Surg Infect. 2002, 3: 161-173. 10.1089/109629602761624171.View ArticleGoogle Scholar
- Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellinger EP, Jernigan J, Gorbach S, Chow AW, Bartlett J: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Treatment guidelines for intra-abdominal infections. Clin Infect Dis. 2003, 37: 997-1005. 10.1086/378702.View ArticlePubMedGoogle Scholar
- Tomera KM, Burdmann EA, Reyna OGP, Jiang Q, Wimmer WM, Woods GL, Richard M: Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Antimicrob Agents Chemother. 2002, 46: 2895-2900. 10.1128/AAC.46.9.2895-2900.2002.View ArticlePubMedPubMed CentralGoogle Scholar
- Wikler MA, Low DE, Cockerill FR, Sheehan DJ, Craig WA, Tenover FC, Dudley MN: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically:approved standard-seventh edition. CLSI (formerly NCCLS). 2006, M7-A7.Google Scholar
- Huang MB, Gay TE, Baker CN, Bannerjee SN, Tenover FC: Two per cent sodium chloride is required for susceptibility testing of staphylococci with oxacillin when using agar-based dilution methods. J Clin Microbiol. 1993, 31: 2683-2688.PubMedPubMed CentralGoogle Scholar
- Tomasz A, Drugeon HB, de Lencastre HM, Jabes D, McDougal L, Bille J: New mechanism for methicillin resistance in Staphylococcus aureus:clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding capacity. Antimicrob Agents Chemother. 1989, 33: 1869-1874.View ArticlePubMedPubMed CentralGoogle Scholar
- Ubukata K, Nakagami S, Nitta A, Yamane A, Kawakami S, Sugiura M, Konno A: Rapid detection of the mecA gene in methicillin-resistant staphylococci by enzymatic detection of polymerase chain reaction products. Clin Microbiol. 1992, 30 (7): 1728-1733.Google Scholar
- Rybak MJ, LaPente KL: Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacother. 2005, 25: 74-85. 10.1592/phco.126.96.36.199620.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/7/79/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.